Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
2018
Abstract Background The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib, in combination with fulvestrant therapy, prolongs progression-free survival among patients with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. We report the results of a prespecified analysis of overall survival. Methods We randomly assigned patients with hormone-receptor–positive, HER2-negative advanced breast cancer who had progression or relapse during previous endocrine therapy to receive palbociclib plus fulvestrant or placebo plus fulvestrant. We analyzed overall survival; the effect of palbociclib according to the prespecified stratification factors of presence or absence of sensitivity to endocrine therapy, presence or absence of visceral metastatic disease, and menopausal status; the efficacy of subsequent therapies after disease progression; and safety. Results Among 521 patients who underwent randomization, the median overall survival was 34.9 mont...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
12
References
414
Citations
NaN
KQI